Submit changes to labels and Patient Information Leaflets as a self-certification

AI Summary

This regulatory guidance outlines the legal obligations for pharmaceutical companies under Regulation 267 of the Human Medicines Regulations (2012) regarding the submission of packaging and leaflet mock-ups to the UK licensing authority. The framework applies to both initial license applications and any subsequent modifications that are not linked to changes in the Summary of Product Characteristics (SmPC). To ensure compliance, license holders are required to submit visual representations of their product labeling and patient information leaflets for official review. The guidance establishes a dual-track submission system: the standard procedure involves a self-certification route, which provides an efficient mechanism for companies to register minor updates. However, more significant changes categorized under classifications P1 through P4 necessitate a full assessment by regulatory officials to verify accuracy and safety. While this document does not reference specific company names, inspection dates, or individual violations, it sets the mandatory standards for all applicants in the UK market. Entities must carefully evaluate their proposed changes to determine if they qualify for self-certification or require the more rigorous full assessment path. Adhering to these requirements is essential for maintaining a valid marketing authorization and ensuring that patient-facing materials remain clear, accurate, and legally compliant throughout the product lifecycle.